Retrolective cohort study of an additive therapy with an oral enzyme preparation in patients with multiple myeloma

Sakalová, A; Bock, Paul R.; Dedik, Ladislav; Hanisch, Jürgen; Schiess, W; Gazová, S; Chabronová, I; Holománová, D; Mistrík, Martin; Hrubisko, M

doi:10.1007/s002800170008

Cited by 33 publications

(28 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In the Slovak Republic an oral enzyme supplement was tested in a placebo-controlled trial of multiple myeloma. For stage III multiple myeloma, control group survival was 47 months, compared to 83 months (a 3 year gain) for patients who took the oral enzymes for more than 6 months [174]. …”

Section: Reviewmentioning

confidence: 99%

Nutrition and cancer: A review of the evidence for an anti-cancer diet

Donaldson¹

2004

Nutr J

548

344

View full text Add to dashboard Cite

It has been estimated that 30–40 percent of all cancers can be prevented by lifestyle and dietary measures alone. Obesity, nutrient sparse foods such as concentrated sugars and refined flour products that contribute to impaired glucose metabolism (which leads to diabetes), low fiber intake, consumption of red meat, and imbalance of omega 3 and omega 6 fats all contribute to excess cancer risk. Intake of flax seed, especially its lignan fraction, and abundant portions of fruits and vegetables will lower cancer risk. Allium and cruciferous vegetables are especially beneficial, with broccoli sprouts being the densest source of sulforophane. Protective elements in a cancer prevention diet include selenium, folic acid, vitamin B-12, vitamin D, chlorophyll, and antioxidants such as the carotenoids (α-carotene, β-carotene, lycopene, lutein, cryptoxanthin). Ascorbic acid has limited benefits orally, but could be very beneficial intravenously. Supplementary use of oral digestive enzymes and probiotics also has merit as anticancer dietary measures. When a diet is compiled according to the guidelines here it is likely that there would be at least a 60–70 percent decrease in breast, colorectal, and prostate cancers, and even a 40–50 percent decrease in lung cancer, along with similar reductions in cancers at other sites. Such a diet would be conducive to preventing cancer and would favor recovery from cancer as well.

show abstract

Section: Reviewmentioning

confidence: 99%

Nutrition and cancer: A review of the evidence for an anti-cancer diet

Donaldson¹

2004

Nutr J

548

344

View full text Add to dashboard Cite

show abstract

“…Additive therapy with OE given for more than 6 months decreased the hazard of death for patients at all stages of disease by approximately 60%. 53 In stage 3 patients, median survival was 47 months in the control group versus 83 months for the patients treated with OE, for a 3-year gain. 53 2001.…”

Section: Current Situationmentioning

confidence: 99%

“…53 In stage 3 patients, median survival was 47 months in the control group versus 83 months for the patients treated with OE, for a 3-year gain. 53 2001. Prakash S. Dale et al, Maharashtra, India, tested the effects of radiation therapy in a prospective randomized controlled trial (RCT) of 120 patients with stages 2a, 2b, or 3b carcinomas of the uterine cervix.…”

Section: Current Situationmentioning

confidence: 99%

Enzymes, Trophoblasts, and Cancer: The Afterlife of an Idea (1924-2008)

Moss¹

2008

Integr Cancer Ther

View full text Add to dashboard Cite

In the early 20th century, advocacy of the enzyme therapy of cancer was primarily the work of one man, John Beard, DSc (1858-1924). He and his collaborators made a determined effort to establish this mode of therapy, especially in the years 1905 to 1911. Despite a brief flowering of international interest, Beard's efforts came to naught. During the 20th century, there was a succession of American researchers who continued to investigate this topic. This included Marshall William McDuffie, MD (1882-1945), Frank LeForest Morse, MD (1876-1953), Franklin Lloyd Shively, MD (1887-1971), and William Donald Kelley (1926-2005). In central Europe, India, and other parts of the globe, the use of pancreatic enzymes as an adjuvant treatment for cancer has become a fairly routine practice, at least among those doctors who utilize complementary and alternative medicine (CAM). It is also a well-established method for reducing inflammation and mitigating the adverse effects of cytotoxic treatment.

show abstract

“…Since 1987, Sakalova et al 24 have treated patients with internationally recommended standard therapies and complementarily added standardized enzyme mixtures containing trypsin, chymotrypsin, and papain. In 1997, the data of all patients treated and documented for plasmacytoma in the context of an optimized retrospective cohort study in parallel groups were gathered.…”

Section: Systemic Enzyme Therapy In Plasmacytoma Patients: a Gep-compmentioning

confidence: 99%

Proteolytic Enzyme Therapy in Evidence-Based Complementary Oncology: Fact or Fiction?

Beuth

2008

Integr Cancer Ther

View full text Add to dashboard Cite

Systemic enzyme therapy was recently subjected to experimental investigations and to rigorous clinical studies in cancer patients. The designs of the relevant clinical cohort studies followed the guidelines of Good Epidemiological Practice and represent level IIB in evidence-based medicine (EBM). Scientifically sound experimental in vitro and in vivo investigations are far advanced and document promising immunological, anti-inflammatory, anti-infectious, and antitumor/antimetastatic activities of proteolytic enzyme mixtures (containing trypsin, chymotrypsin, and papain) or bromelain. EBM level II clinical studies, which are accepted by the European Union to show safety and efficacy of medical treatments, were performed to evaluate the benefit of complementary systemic enzyme therapy in cancer patients suffering from breast and colorectal cancers and plasmacytoma. These studies demonstrated that systemic enzyme therapy significantly decreased tumor-induced and therapy-induced side effects and complaints such as nausea, gastrointestinal complaints, fatigue, weight loss, and restlessness and obviously stabilized the quality of life. For plasmacytoma patients, complementary systemic enzyme therapy was shown to increase the response rates, the duration of remissions, and the overall survival times. These promising data resulted in an “orphan drug status” designation for a systemic enzyme product, which should motivate further studies on this complementary treatment.

show abstract

Retrolective cohort study of an additive therapy with an oral enzyme preparation in patients with multiple myeloma

Abstract: OEs represent a promising new additive therapy in multiple myeloma which will be further evaluated in a randomized phase III trial in the USA.

Cited by 33 publications

References 0 publications

Nutrition and cancer: A review of the evidence for an anti-cancer diet

Nutrition and cancer: A review of the evidence for an anti-cancer diet

Enzymes, Trophoblasts, and Cancer: The Afterlife of an Idea (1924-2008)

Proteolytic Enzyme Therapy in Evidence-Based Complementary Oncology: Fact or Fiction?

Contact Info

Product

Resources

About